DrugPatentWatch Database Preview
APRACLONIDINE HYDROCHLORIDE - Generic Drug Details
What are the generic drug sources for apraclonidine hydrochloride and what is the scope of apraclonidine hydrochloride patent protection?
Apraclonidine hydrochloride
is the generic ingredient in two branded drugs marketed by Akorn Inc and Novartis Pharms Corp, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for apraclonidine hydrochloride. Three suppliers are listed for this compound.
Summary for APRACLONIDINE HYDROCHLORIDE
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 3 |
Drug Master File Entries: | 3 |
Suppliers / Packagers: | 3 |
Bulk Api Vendors: | 56 |
Clinical Trials: | 1 |
Patent Applications: | 289 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APRACLONIDINE HYDROCHLORIDE |
DailyMed Link: | APRACLONIDINE HYDROCHLORIDE at DailyMed |
Pharmacology for APRACLONIDINE HYDROCHLORIDE
Drug Class | alpha-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists |
Synonyms for APRACLONIDINE HYDROCHLORIDE
1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-, monohydrochloride |
1,4-Benzenediamine, 2,6-dichloro-N(sup 1)-2-imidazolidinylidene-, monohydrochloride |
2-((4-Amino-2,6-dichlorophenyl)imino)imidazolidine monohydrochloride |
2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride |
2-(4-Amino-2,6-dichlorophenylimino)imidazolidine hydrochloride |
2-[(2,6-dichloro-4-aminophenyl)imino]imidazolidine hydrochloride |
2,6-bis(chloranyl)-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
2,6-Dichloro-N(1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride |
2,6-Dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride |
2,6-Dichloro-N(sup 1)-(2-imidazolidinylidene)-1,4-benzenediamine hydrochloride |
2,6-Dichloro-N(sup 1)-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine monohydrochloride |
2,6-Dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)-1,4-benzenediamine Hydrochloride |
2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine hydrochloride |
218A798 |
3,5-Dichloro-4-(2-imidazolidinylidenimino)aniline hydrochloride |
4CH-016312 |
73218-79-8 |
87913-86-8 |
A 0779 |
A837749 |
AC-12705 |
AC1L1BOD |
AK143283 |
AKOS022175501 |
AKOS025401362 |
AL 02145 |
AL-02145 |
ALO-2145 |
AN-6532 |
Aplonidine HCl |
Aplonidine hydrochloride |
Apraclonidine hydrochloride |
Apraclonidine HCl |
Apraclonidine hydrochloride (JAN/USP) |
Apraclonidine hydrochloride [USAN] |
Apraclonidinehydrochloride |
BG0575 |
C-17735 |
C9H10Cl2N4.HCl |
C9H11Cl3N4 |
CAS-73218-79-8 |
CC-24163 |
CCG-221337 |
CHEBI:2789 |
CHEMBL1200379 |
CTK8F7806 |
D01008 |
D2VW67N38H |
DR000985 |
DSSTox_CID_25749 |
DSSTox_GSID_45749 |
DSSTox_RID_81093 |
DTXSID6045749 |
EU-0100033 |
FT-0602878 |
Iopidine ophthalmic solution |
KS-00000MLM |
LP00033 |
LS-29586 |
MFCD00135922 |
MLS000028829 |
MLS006010230 |
MolPort-006-069-427 |
NC 14 hydrochloride |
NCGC00093552-01 |
NCGC00260718-01 |
OTQYGBJVDRBCHC-UHFFFAOYSA-N |
p-Aminoclonidine hydrochloride |
p-Aminoclonidine hydrochloride, solid |
p-Aminoclonidine Monohydrochloride |
S311 |
SCHEMBL41138 |
SMR000058965 |
SR-01000075247 |
SR-01000075247-1 |
ST2409192 |
Tox21_111207 |
Tox21_500033 |
UNII-D2VW67N38H |
US Patents and Regulatory Information for APRACLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020258-001 | Jul 30, 1993 | AT | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
Akorn Inc | APRACLONIDINE HYDROCHLORIDE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 077764-001 | Mar 12, 2009 | AT | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for APRACLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020258-001 | Jul 30, 1993 | ➤ Sign Up | ➤ Sign Up |
Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | ➤ Sign Up | ➤ Sign Up |
Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | ➤ Sign Up | ➤ Sign Up |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:









Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.